Get the Stockscreener App
8.765
9.63%
0.77
Pre-market:
8.70
-0.065
-0.74%
Replimune Group Inc stock is traded at $8.765, with a volume of 1.35M.
It is up +9.63% in the last 24 hours and down -18.99% over the past month.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
See More
Previous Close:
$7.995
Open:
$7.86
24h Volume:
1.35M
Relative Volume:
1.80
Market Cap:
$578.38M
Revenue:
-
Net Income/Loss:
$-209.96M
P/E Ratio:
-2.7737
EPS:
-3.16
Net Cash Flow:
$-176.27M
1W Performance:
+16.71%
1M Performance:
-18.99%
6M Performance:
-22.78%
1Y Performance:
+35.89%
1-Day Range:
$7.83
$9.33
1-Week Range:
$7.38
$9.33
52-Week Range:
$4.92
$17.00
Replimune Group Inc Stock (REPL) Company Profile
Name
Replimune Group Inc
Sector
Industry
Phone
(781) 222-9600
Address
500 UNICORN PARK, WOBURN, MA
Compare REPL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
8.765 | 578.38M | 0 | -209.96M | -176.27M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Apr-17-23 | Resumed | Piper Sandler | Overweight |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-17-20 | Initiated | BTIG Research | Buy |
| Nov-02-20 | Initiated | Jefferies | Buy |
| Oct-15-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-05-20 | Initiated | Barclays | Overweight |
| Sep-04-19 | Initiated | ROTH Capital | Buy |
| Jul-23-19 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| Apr-25-19 | Initiated | Wedbush | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-14-18 | Initiated | JP Morgan | Overweight |
| Aug-14-18 | Initiated | Leerink Partners | Outperform |
View All
Replimune Group Inc Stock (REPL) Latest News
Replimune Group, Inc. (NASDAQ:REPL) Shares Purchased by Geode Capital Management LLC - Defense World
JPMorgan Chase & Co. Has $5.89 Million Stock Holdings in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Alliancebernstein L.P. Sells 48,397 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Vanguard Group Inc. Has $43.55 Million Holdings in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA - MSN
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | REPL Stock News - GuruFocus
Sei Investments Co. Purchases New Stake in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Replimune stock target raised to $22 at H.C. Wainwright - MSN
Navigating Uncertainty: Replimune Group’s Strategic Challenges Amid Clinical Trials and Global Risks - MSN
Is Replimune Group (NASDAQ:REPL) A Risky Investment? - simplywall.st
Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of “Buy” from Analysts - Defense World
KLP Kapitalforvaltning AS Takes Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Corebridge Financial Inc. Reduces Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Group, Inc. (NASDAQ:REPL) Stake Lifted by American Century Companies Inc. - Defense World
Teacher Retirement System of Texas Takes $189,000 Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Group (NASDAQ:REPL) Trading Down 7.6%What's Next? - MarketBeat
SynOx Therapeutics Announces Board Chair Transition to Align with Advancing Regulatory and Commercialization Strategy - The Manila Times
Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Swiss National Bank - Defense World
Charles Schwab Investment Management Inc. Has $6.16 Million Stake in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Victory Capital Management Inc. Purchases Shares of 44,880 Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Bank of New York Mellon Corp Increases Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Group, Inc. (NASDAQ:REPL) Holdings Cut by AlphaQuest LLC - Defense World
Replimune Group, Inc. (NASDAQ:REPL) Receives $19.43 Average Price Target from Analysts - Defense World
Arizona State Retirement System Invests $156,000 in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Financial Metrics Check: Replimune Group Inc (REPL)’s Ratios for Trailing Twelve Months - The Dwinnex
Replimune Group Appoints New Director, Grants Stock Options By Investing.com - Investing.com Australia
Replimune Group Appoints New Director, Grants Stock Options - Investing.com
Replimune Group Appoints Michael Goller To Board, Increases Board Size To Ten -March 07, 2025 at 05:04 pm EST - Marketscreener.com
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) -March 07, 2025 at 04:11 pm EST - Marketscreener.com
Rhumbline Advisers Grows Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Raises $55 Million To Advance Its Oncolytic Immunotherapy Programs - Bain Capital
New York State Common Retirement Fund Purchases 31,231 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World
JPMorgan Chase & Co. Increases Replimune Group (NASDAQ:REPL) Price Target to $18.00 - MarketBeat
Replimune Group (NASDAQ:REPL) Price Target Raised to $18.00 - Defense World
Replimune Group (NASDAQ:REPL) Stock Price Up 6.1%What's Next? - MarketBeat
Replimune Group, Inc. (NASDAQ:REPL) Receives $19.29 Average Price Target from Brokerages - Defense World
Replimune Group, Inc. (NASDAQ:REPL) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Replimune Group, Inc. (NASDAQ:REPL) Short Interest Update - MarketBeat
Replimune's SWOT analysis: oncolytic immunotherapy stock poised for FDA approval - Investing.com
Possible Bearish Signals With Replimune Group Insiders Disposing Stock - Simply Wall St
Leerink Partnrs Predicts Weaker Earnings for Replimune Group - Defense World
FY2025 EPS Estimates for Replimune Group Lowered by Wedbush - MarketBeat
Replimune Group (NASDAQ:REPL) Announces Quarterly Earnings Results - MarketBeat
HC Wainwright Forecasts Strong Price Appreciation for Replimune Group (NASDAQ:REPL) Stock - MarketBeat
Replimune Group Inc Stock (REPL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
4.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):